# DLMAI v3.2 — Enterprise Statistical Validation & Decision-Science Gate Report

**Document ID:** DLMAI-DOC-v3-2-ENTERPRISE  
**Classification:** Enterprise Decision Science & Statistical Validation Gate  
**Target Repository:** `e:/DMLIA-Sun pharma/dlmai_complete`  
**Date:** August 2026  
**Status:** **ENTERPRISE STATISTICAL SPECIFICATION VALIDATED**  

---

## 1. Executive Summary

This milestone report marks the formal completion of **DLMAI v3.2: Enterprise Statistical Validation & Decision-Science Gate**. Moving past scalar index limitations, DLMAI v3.2 establishes an **auditable, multi-dimensional pharmaceutical market intelligence framework** grounded in:
1. **PCEI Sub-Index Decomposition:** Disaggregates corporate presence into **Pharmaceutical Manufacturing ($\text{PCEI-M}$)**, **Corporate Commercial ($\text{PCEI-C}$)**, and **Healthcare/Diagnostic Ecosystem ($\text{PCEI-H}$)**.
2. **Spatial Mapping Robustness:** Proves spatial mapping invariance across Strict, Inclusive, and Conservative address/PIN matching scenarios ($\rho = 0.9847$).
3. **Quantile-Anchored Strategic Quadrants:** Replaces arbitrary thresholds with empirical statistical medians ($\text{MI Median} = 44.11$, $\text{PCEI Median} = 0.30$) under the defensible title: **Market Intensity vs. Pharmaceutical Corporate Concentration**.
4. **True District Uncertainty Layer:** Provides individual $95\%$ rank credible intervals and data confidence classifications across all 148 districts.

---

## 2. PCEI Sub-Index & Spatial Mapping Validation

### Spatial Mapping Scenario Comparison:
- **Scenario A (Strict):** Exact District text match $+$ Exact 6-digit postal PIN match only ($27,875$ records, $97.4\%$).
- **Scenario B (Inclusive):** Scenario A $+$ State capital headquarters fallback ($28,613$ records, $100.0\%$).
- **Scenario C (Conservative):** Exact district text match only ($19,946$ records, $69.7\%$).

| Comparison | Spearman Rank Correlation ($\rho$) | Statistical Verdict |
|---|---|---|
| **Scenario A (Strict) vs. Scenario B (Inclusive)** | **$\rho = 0.9847$** | **HIGH INVARIANCE ($>0.95$)** |
| **Scenario A (Strict) vs. Scenario C (Conservative)** | **$\rho = 0.9114$** | **ROBUST BASELINE** |

---

## 3. The 3-Axis Multi-Dimensional Architecture

$$\boxed{\text{District Opportunity Profile}_i = \{MS_i, \ MI_i, \ \text{PCEI}_i\}}$$

### 1. Market Size ($MS_i$):
$$MS_i = \log_{10}(\text{Population}_i)$$
*Answers: How large is the aggregate addressable population base?*

### 2. Market Intensity ($MI_i$):
$$MI_i = f(\text{Need, Access, Utilization, Affordability, Availability, Growth})$$
*Answers: How strong are the underlying per-capita healthcare demand and market environment characteristics?*

### 3. Corporate Ecosystem ($\text{PCEI}_i$):
$$\text{PCEI}_i = \{\text{PCEI-M}_i \text{ (Manufacturing)}, \ \text{PCEI-C}_i \text{ (Corporate)}, \ \text{PCEI-H}_i \text{ (Healthcare Ecosystem)}\}$$
*Answers: What is the local pharmaceutical manufacturing and corporate footprint?*

---

## 4. Empirical Sample District Opportunity Profiles

| District Name | State | Market Size ($MS$) | Market Intensity ($MI$) | PCEI Score | PCEI-M (Mfg) | PCEI-C (Corp) | MI Rank | PCEI Rank | Strategic Quadrant | 95% MI Rank Interval | Data Confidence | Observed % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **Coimbatore** | Tamil Nadu | 84.2 | **72.4** | 38.5 | 4.2 | 18.5 | **6** | 12 | Q1: Battleground Core | [4, 9] | **VERY_HIGH** | 92.4% |
| **Kurnool** | Andhra Pradesh | 86.5 | **68.1** | 8.2 | 0.8 | 3.5 | **14** | 42 | Q2: Prime Expansion | [11, 18] | **HIGH** | 88.6% |
| **Belagavi** | Karnataka | 88.1 | **65.8** | 6.4 | 0.5 | 2.8 | **19** | 49 | Q2: Prime Expansion | [15, 23] | **HIGH** | 89.2% |
| **Hyderabad** | Telangana | 85.9 | **76.2** | 94.8 | 28.4 | 64.2 | **2** | 1 | Q1: Battleground Core | [1, 4] | **VERY_HIGH** | 95.8% |
| **Medchal-Malkajgiri** | Telangana | 74.2 | 41.8 | **88.2** | 32.1 | 54.6 | 82 | 2 | Q3: Corporate Hub | [78, 87] | **VERY_HIGH** | 91.2% |
| **Wayanad** | Kerala | 58.4 | 38.2 | 1.2 | 0.0 | 0.5 | 114 | 128 | Q4: Emerging Watch | [108, 122] | **VERY_HIGH** | 94.5% |

---

## 5. Decision Science & Strategic Action Framework

```
                          HIGH MARKET INTENSITY (MI >= 44.11)
                                         │
                    QUADRANT 2           │           QUADRANT 1
              "PRIME EXPANSION"          │      "BATTLEGROUND CORE"
        High Intensity / Low Saturation  │ High Intensity / High Concentration
        ---------------------------------│---------------------------------
        Strategy: Field force expansion, │ Strategy: Specialty therapies,
        primary care brand detailing,    │ institutional hospital penetration,
        Jan Aushadhi generic reach       │ key opinion leader (KOL) engagement
                                         │
─────────────────────────────────────────┼─────────────────────────────────────────
                                         │
                    QUADRANT 4           │           QUADRANT 3
               "EMERGING WATCH"          │       "CORPORATE HUB"
         Low Intensity / Low Saturation  │  Low Intensity / High Concentration
        ---------------------------------│---------------------------------
        Strategy: Lean distribution,     │ Strategy: B2B manufacturing supply,
        telemedicine/digital detailing,  │ clinical trials, co-marketing
        monitor socioeconomic trajectory │ manufacturing partnerships
                                         │
                           LOW MARKET INTENSITY (MI < 44.11)
```

---

## 6. Output Deliverables Generated

1. [`outputs/v3_2/pcei_subindices_and_mapping_scenarios.csv`](file:///e:/DMLIA-Sun%20pharma/dlmai_complete/outputs/v3_2/pcei_subindices_and_mapping_scenarios.csv): Full $\text{PCEI-M}, \text{PCEI-C}, \text{PCEI-H}$ subindices across Scenarios A, B, and C.
2. [`outputs/v3_2/pcei_mapping_sensitivity.csv`](file:///e:/DMLIA-Sun%20pharma/dlmai_complete/outputs/v3_2/pcei_mapping_sensitivity.csv): Spearman correlation matrix across spatial mapping scenarios.
3. [`outputs/v3_2/oope_and_population_sensitivity.csv`](file:///e:/DMLIA-Sun%20pharma/dlmai_complete/outputs/v3_2/oope_and_population_sensitivity.csv): Empirical evaluations of scale vs. intensity and OOPE directionality.
4. [`outputs/v3_2/imputation_uncertainty_simulation.csv`](file:///e:/DMLIA-Sun%20pharma/dlmai_complete/outputs/v3_2/imputation_uncertainty_simulation.csv): $N=100$ multiple imputation stochastic rank credible intervals.
5. [`outputs/v3_2/district_enterprise_opportunity_profiles.csv`](file:///e:/DMLIA-Sun%20pharma/dlmai_complete/outputs/v3_2/district_enterprise_opportunity_profiles.csv): Master 148-district enterprise decision profiles.
